Identification of qnrE3 and qnrE4, New Transferable Quinolone Resistance qnrE Family Genes Originating from Enterobacter mori and Enterobacter asburiae, Respectively.

Antimicrobial Agents and Chemotherapy
Chen WangMinggui Wang

Abstract

The qnrE family was designated in 2017. To date, two qnrE alleles have been discovered that are carried by plasmids. Here, we identified a new quinolone resistance gene, qnrE3, in the chromosome of Enterobacter mori clinical isolate 08-091 in China. qnrE3 conferred decreased susceptibility to fluoroquinolones, similar to qnrE1 and qnrE2. To investigate the precise origin of qnrE1, qnrE2, and qnrE3, 79 qnrE-bearing strains producing 30 qnrE variants were retrieved from the NCBI database. Phylogenetic analysis illustrated two major clusters, QnrEEmo and QnrEEas, produced mainly by the E. mori and E. asburiae strains, respectively. Comparison of the genetic context of qnrE alleles demonstrated that qnrE3 and qnrEEas2 alleles presumably were captured by ISEcp1 and mobilized from the E. mori and E. asburiae strains to the E. xiangfangensis and Escherichia coli strains, respectively. qnrEEas2 was proposed to be named qnrE4, since it has spread to another genus. All the qnrE alleles were harbored by the Enterobacter species, except those captured by ISEcp1 and mobilized into other species of Enterobacterales. E. mori is probably the source of qnrE1 to qnrE3 alleles, and E. asburiae is the reservoir of qnrE4.

References

Mar 31, 1998·Lancet·L Martínez-MartínezG A Jacoby
Sep 6, 2003·Applied and Environmental Microbiology·Harald Hoffmann, Andreas Roggenkamp
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Mami HataKenji Sakae
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·George A JacobyDavid C Hooper
Apr 23, 2008·Antimicrobial Agents and Chemotherapy·George JacobyMinggui Wang
Jul 5, 2008·Emerging Infectious Diseases·Erica L FonsecaAna C P Vicente
Mar 5, 2009·Antimicrobial Agents and Chemotherapy·Minghua WangMinggui Wang
Oct 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Michael Richter, Ramon Rosselló-Móra
Jan 11, 2011·International Journal of Systematic and Evolutionary Microbiology·Bo ZhuYong-Pin Duan
Aug 17, 2011·Antimicrobial Agents and Chemotherapy·George A JacobyDavid C Hooper
Dec 25, 2013·BMC Genomics·Cristiane C ThompsonFabiano L Thompson
Mar 10, 2015·Systematic and Applied Microbiology·Ramon Rosselló-Móra, Rudolf Amann
Jul 4, 2015·Nature Reviews. Drug Discovery·Ruben TommasiAlita A Miller
Oct 31, 2016·Genomics, Proteomics & Bioinformatics·Hengyun LuZemin Ning
Nov 1, 2016·Nature Methods·Chen-Shan ChinMichael C Schatz
May 4, 2018·Molecular Biology and Evolution·Sudhir KumarKoichiro Tamura
May 18, 2019·Nature Communications·Jan P Meier-Kolthoff, Markus Göker
Jul 19, 2019·Clinical Microbiology Reviews·Anne Davin-RegliJean-Marie Pagès
Dec 1, 2019·International Journal of Antimicrobial Agents·Laura DabosThierry Naas
Jan 6, 2021·Communications Biology·Stefan EbmeyerD G Joakim Larsson

❮ Previous
Next ❯

Datasets Mentioned

BETA
CP071064.1
CP071063.1
CP027699.1

Methods Mentioned

BETA
electrophoresis

Software Mentioned

ResFinder
MEGA X
BLASTN
MEGA
RAST
JSpecies Distance Calculator
BLASTP

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.